These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 36787738)

  • 1. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
    Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
    Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
    Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
    Front Immunol; 2022; 13():950134. PubMed ID: 36003379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
    Bewersdorf JP; Zeidan AM
    Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
    Madanat YF; Xie Z; Zeidan AM
    Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
    Madanat Y; Sekeres MA
    Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
    Ganan-Gomez I; Yang H; Ma F; Montalban-Bravo G; Thongon N; Marchica V; Richard-Carpentier G; Chien K; Manyam G; Wang F; Alfonso A; Chen S; Class C; Kanagal-Shamanna R; Ingram JP; Ogoti Y; Rose A; Loghavi S; Lockyer P; Cambo B; Muftuoglu M; Schneider S; Adema V; McLellan M; Garza J; Marchesini M; Giuliani N; Pellegrini M; Wang J; Walker J; Li Z; Takahashi K; Leverson JD; Bueso-Ramos C; Andreeff M; Clise-Dwyer K; Garcia-Manero G; Colla S
    Nat Med; 2022 Mar; 28(3):557-567. PubMed ID: 35241842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
    Cogle CR; Kurtin SE; Bentley TG; Broder MS; Chang E; Megaffin S; Fruchtman S; Petrone ME; Mukherjee S
    Oncologist; 2017 Apr; 22(4):379-385. PubMed ID: 28283585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
    Linder K; Lulla P
    Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
    Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
    J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with lower-risk myelodysplastic syndromes.
    Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
    Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
    Uy N; Singh A; Gore SD; Prebet T
    Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.